Leading healthcare firm GSK is to invest $30bn in US research and development and supply chain infrastructure over the next five years.
The investment includes $1.2bn in advanced manufacturing facilities and AI and advanced digital technologies, to deliver new biopharma factories and laboratories.
GSK partners with industrial and medical gas suppliers as part of its manufacturing and supply chain operations for its cell and gene therapy products. It also uses gases in some of its products, such as the propellant in some inhalers.
Energy sustainability is another key focus as it aims to reduce its environmental impact by lowering greenhouse gas emissions across its value chain. It is targeting 100% renewable electricity for its operations by 2030.
… to continue reading this article and more, please login, register for free, or consider subscribing to gasworld
You’ve reached your weekly limit to access free articles!
Want to keep reading?
Please register for free and create a profile to gain access to this full article and gasworld’s daily news.
For access to more content including our monthly digital magazines, subscriber-only features or columns and all our other gasworld archives, please consider subscribing.
Alternatively, you can continue reading more articles as a guest on Wednesday, 24th September at 10:29AM
